Hints and tips:
...Analyst estimates for Sandoz’s potential market capitalisation range from $18bn to $25bn, which would be slightly smaller than eyecare business Alcon, which Novartis spun off in 2019 and listed at a valuation...
...The Canadian eyecare products maker successfully raised $630mn this week. That made it the second biggest initial public offering in 2022 after private equity firm TPG’s offering in January....
...Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, had been aiming to raise up to $840mn, on Thursday evening but eventually sold at $18 per share, raising $630mn....
...Founded in 1853 by John Jacob Bausch in Rochester, New York, Bausch + Lomb grew to be a leader in the lucrative eyecare field....
...As well as Botox, Allergan makes drugs that are used in eyecare, gastroenterology and to treat the central nervous system....
...With Allergan, AbbVie will add Botox as well as a host of drugs that are used in eyecare, gastroenterology and to treat the central nervous system to its portfolio....
...Allergan’s portfolio is best known for Botox, a wildly popular non-surgical cosmetic treatment, but the company also makes drugs that are used in eyecare, gastroenterology and to treat the central nervous...
...The $23bn eyecare market is growing at 4 per cent a year, and is likely to be among the faster growing medical sectors....
...In little over a year, Mr Narasimhan has moved quickly to reshape Novartis, selling its 36.5 per cent stake in a consumer joint venture with GlaxoSmithKline and announcing plans to spin off its Alcon eyecare...
...The intervention by Henry Waxman, the former Democrat congressman, comes amid mounting criticism of Allergan in Washington, after it transferred patents protecting a $1.5bn eyecare drug to a tribe in an...
...Swiss drugmaker Novartis plans to spin off its Alcon eyecare unit, possibly worth as much as $25bn, as new chief executive Vas Narasimhan pushes ahead with his focus on core medicines businesses....
...the helm in February, Vas Narasimhan has moved quickly to reshape the company, selling its 36.5 per cent stake in a consumer joint venture with GlaxoSmithKline and announcing plans to spin off its Alcon eyecare...
...Novartis is spinning off its eyecare unit. Pfizer recently tried and failed to sell its own consumer health division....
...Back in 2010, the company decided to buy eyecare group Alcon. Markets could not see the point. Novartis has a new chief executive, Vasant Narasimhan. He will spin off most of Alcon next year....
...Overlaps centre on the eyecare, gastroenterology and central nervous system divisions. Neither company is in great shape. Both are valued at just over 10 times forward earnings....
...Switzerland’s Novartis has moved closer to spinning off and possibly listing its under-performing Alcon eyecare business, in a deal which could value the unit at more than $25bn....
...Novartis has already announced plans to spin off and list its under-performing Alcon eyecare business, which could be worth more than $25bn, but has delayed any move until 2019....
...Swiss drugmaker Novartis hopes to spin off and list its under-performing Alcon eyecare business, which could be worth more than $25bn, but has delayed any move until 2019....
...Mr Narasimhan is expected to use the funds to expand “core” business areas — innovative prescription medicines, as well as oncology, generics and eyecare — via organic growth but also through “bolt on” acquisitions...
...The most vexing issue is what to do with Alcon, the eyecare division for which Novartis paid Nestlé $51.6bn in 2010....
...This eyecare treatment is the company’s second biggest drug programme after Botox and has $1.4bn in annual sales....
...Rebounding sales at Novartis’s eyecare division Alcon enabled the Swiss drugmaker to beat analyst expectations for second-quarter earnings....
...Novartis is in the process of reviewing what to do with Alcon, the troublesome eyecare business it bought for $51bn in 2010....
...Spinning off the Alcon eyecare business could create a company with a market capitalisation of between $25bn and $35bn, Mr Jimenez suggested....
...However, last year trials of the diabetic lens were postponed with no firm replacement date and Novartis is widely thought to be considering the sale of Alcon, its eyecare unit....
International Edition